The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.

MS experts are recommending updates to the 2017 McDonald diagnostic criteria that aim to make diagnosis easier, faster and more accurate.

The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...

Hetronifly in combination with chemotherapy was shown to improve survival of patients with extensive stage small cell lung ...

The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...

The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) recommended the granting of ...

The European Medicines Agency approved Afqlir and Opuviz to treat age-related macular degeneration while reiterating its ...

Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ...

"Although the effect on overall anaemia did not differ, intravenous iron reduced the prevalence of iron deficiency to a ...

The multitarget stool DNA test was better at detecting advanced serrated colorectal lesions than other stool-based tests, a ...

According to US secondary stroke prevention guidelines, patients with ESUS should not be treated with anticoagulants or ...

Air pollution, high temperatures, and metabolic risk factors are driving large global increases in stroke cases and deaths, new data showed.